chartexchange

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study

PR Newswire | Nov 3, 2026 8:15 AM EST

Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck® cell collection in under two minutes NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a...

Read original article